Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection.

Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, Walter R, Fuchs D, Brew BJ, Cinque P, Robertson K, Hagberg L, Zetterberg H, Gisslén M, Spudich S.

J Infect Dis. 2013 Jun 1;207(11):1703-12. doi: 10.1093/infdis/jit088. Epub 2013 Mar 4.

2.

Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection.

Peterson J, Gisslen M, Zetterberg H, Fuchs D, Shacklett BL, Hagberg L, Yiannoutsos CT, Spudich SS, Price RW.

PLoS One. 2014 Dec 26;9(12):e116081. doi: 10.1371/journal.pone.0116081. eCollection 2014.

3.

Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection.

Peluso MJ, Valcour V, Ananworanich J, Sithinamsuwan P, Chalermchai T, Fletcher JL, Lerdlum S, Chomchey N, Slike B, Sailasuta N, Gisslén M, Zetterberg H, Spudich S; RV254/SEARCH 010 and SEARCH 011 Study Teams.

J Infect Dis. 2015 Dec 1;212(11):1759-67. doi: 10.1093/infdis/jiv296. Epub 2015 May 20.

4.

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study.

Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H.

EBioMedicine. 2015 Nov 22;3:135-40. doi: 10.1016/j.ebiom.2015.11.036. eCollection 2016 Jan.

5.

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection.

Gisslén M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, Spudich S, Hagberg L, Rosengren L, Price RW, Zetterberg H.

BMC Neurol. 2009 Dec 22;9:63. doi: 10.1186/1471-2377-9-63.

6.

Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.

Jespersen S, Pedersen KK, Anesten B, Zetterberg H, Fuchs D, Gisslén M, Hagberg L, Trøseid M, Nielsen SD.

BMC Infect Dis. 2016 Apr 21;16:176. doi: 10.1186/s12879-016-1510-6.

7.

Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy.

Rahimy E, Li FY, Hagberg L, Fuchs D, Robertson K, Meyerhoff DJ, Zetterberg H, Price RW, Gisslén M, Spudich S.

J Infect Dis. 2017 Apr 1;215(7):1132-1140. doi: 10.1093/infdis/jix013.

PMID:
28368497
8.

Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients.

Jessen Krut J, Mellberg T, Price RW, Hagberg L, Fuchs D, Rosengren L, Nilsson S, Zetterberg H, Gisslén M.

PLoS One. 2014 Feb 11;9(2):e88591. doi: 10.1371/journal.pone.0088591. eCollection 2014.

9.

Cell-free mitochondrial DNA in CSF is associated with early viral rebound, inflammation, and severity of neurocognitive deficits in HIV infection.

Pérez-Santiago J, Schrier RD, de Oliveira MF, Gianella S, Var SR, Day TR, Ramirez-Gaona M, Suben JD, Murrell B, Massanella M, Cherner M, Smith DM, Ellis RJ, Letendre SL, Mehta SR.

J Neurovirol. 2016 Apr;22(2):191-200. doi: 10.1007/s13365-015-0384-5. Epub 2015 Oct 1.

10.

Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy.

Anderson AM, Harezlak J, Bharti A, Mi D, Taylor MJ, Daar ES, Schifitto G, Zhong J, Alger JR, Brown MS, Singer EJ, Campbell TB, McMahon DD, Buchthal S, Cohen R, Yiannoutsos C, Letendre SL, Navia BA; HIV Neuroimaging Consortium.

J Acquir Immune Defic Syndr. 2015 May 1;69(1):29-35. doi: 10.1097/QAI.0000000000000532.

11.

CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease.

Anderson AM, Fennema-Notestine C, Umlauf A, Taylor MJ, Clifford DB, Marra CM, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Simpson DM, Morgello S, Grant I, Letendre SL; CHARTER Group.

J Neurovirol. 2015 Oct;21(5):559-67. doi: 10.1007/s13365-015-0359-6. Epub 2015 Jun 12.

12.

Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study.

Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A.

Eur J Neurol. 2010 Mar;17(3):377-82. doi: 10.1111/j.1468-1331.2009.02808.x. Epub 2009 Oct 21.

PMID:
19845747
13.

Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.

Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW.

J Infect Dis. 2011 Sep 1;204(5):753-60. doi: 10.1093/infdis/jir387.

14.

HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study.

Cysique LA, Moffat K, Moore DM, Lane TA, Davies NW, Carr A, Brew BJ, Rae C.

PLoS One. 2013 Apr 19;8(4):e61738. doi: 10.1371/journal.pone.0061738. Print 2013.

15.

Association between Plasma Homocysteine Levels and Neuronal Injury in HIV Infection.

Ahlgren E, Hagberg L, Fuchs D, Andersson LM, Nilsson S, Zetterberg H, Gisslén M.

PLoS One. 2016 Jul 21;11(7):e0158973. doi: 10.1371/journal.pone.0158973. eCollection 2016.

16.

Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients.

Calcagno A, Atzori C, Romito A, Vai D, Audagnotto S, Stella ML, Montrucchio C, Imperiale D, Di Perri G, Bonora S.

J Neurovirol. 2016 Feb;22(1):88-92. doi: 10.1007/s13365-015-0371-x. Epub 2015 Aug 6.

PMID:
26246357
17.

Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders.

McGuire JL, Gill AJ, Douglas SD, Kolson DL; CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) group.

J Neurovirol. 2015 Aug;21(4):439-48. doi: 10.1007/s13365-015-0333-3. Epub 2015 Mar 17.

18.

Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation.

Wang SX, Ho EL, Grill M, Lee E, Peterson J, Robertson K, Fuchs D, Sinclair E, Price RW, Spudich S.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):303-10. doi: 10.1097/QAI.0000000000000167.

19.

Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex.

Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L.

J Infect Dis. 2007 Jun 15;195(12):1774-8. Epub 2007 May 2.

PMID:
17492593
20.

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration.

Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, Kramer JH, Rabinovici G, Ahlijanian M, Miller BL, Seeley W, Grinberg LT, Rosen H, Meredith J Jr, Boxer AL.

Ann Neurol. 2014 Jan;75(1):116-26. doi: 10.1002/ana.24052. Epub 2014 Jan 2.

Supplemental Content

Support Center